What an incredible year for the SHARP CRC!
This year, SHARP members came together at the ERS Congress in Amsterdam to reflect on a year full of inspiring collaboration. We’ve achieved so much together! From a range of impactful projects with publications about to be published in impactful peer review journal, to the tenure of the SHARP Workshop for National Leads & Rising Stars, it’s been a period of growth and success. Many of the ongoing project end up with meaningful results and are now in manuscript writing phase. And the momentum doesn’t stop here—with several exciting new projects including the SHARP Clinical Protocol to harmonise Severe Asthma care and data collection
among SHARP countries!
We’re thrilled by these achievements and even more excited for what’s to come. Let’s continue this amazing journey together!
Achievements
- SHARP has expanded to 30 countries with 12 publications to date.
- Federated Analysis Platform now connects 8 national registries, with Germany and Austria soon joining.
- 15 countries contribute via the SHARP Central Registry, with Macedonia and Ukraine expected to join.
- 11 abstracts were presented at the ERS Congress, reflecting strong scientific activity and engagement.
Ongoing Projects
- Multimorbidity Project: three manuscripts (phenotypes, steroid-related comorbidities, and physician survey) progressing; patient survey ongoing.
- Severe Asthma Questionnaire Study: 457 patients from 14 sites; assessing QoL, asthma control, and app validation.
- Aspergillus Sensitisation Analysis: 13,000 patients analysed; paper in preparation to explore biologic response in this subgroup.
- Elderly Patients (ELSA Study): data from 23 countries; findings show under prescription of biologics and age-related differences.
- Smoking and Biologic Effectiveness: biologics work across smoking groups, but smokers underrepresented and undertreated.
- Obesity and Severe Asthma: high female prevalence; minimal treatment differences; ongoing longitudinal analysis.
- Patient Experience with Biologics Survey: 626 patients, 16 countries; 41% report “life-changing” responses; publication planned next year.
- National Lead Forum & Advocacy Survey: 21 countries; identified strengths (specialist access), opportunities (registry growth), and threats (late referral, funding limits); paper in preparation.
Future Projects / Strategic Direction
- Clinical Protocol Development: creating a European standard for severe asthma assessment and data collection.
- Prospective Study: planned enrolment of 14,000 patients for large-scale analysis of treatment response and remission.
- Integration with Primary Care: strengthening collaboration and shared management models.
- Next Severe Asthma Patient Conference (Nov 22): focus on comorbidities and new medications, with multilingual accessibility.
